Physician profile
Brian D Lee
NPI 1770505547
$841.41
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $60.84 · 2021: $253 · 2022: $233 · 2024: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $128.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $250.53 | 2020-2024 | |
| Abiomed | $92.81 | 2024 | Impella |
| Almirall LLC | $80.49 | 2021-2022 | |
| Genzyme Corporation | $61.72 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $44.52 | 2019 | |
| Lilly USA, LLC | $35.27 | 2019-2022 | |
| Incyte Corporation | $29.22 | 2022 | |
| Janssen Biotech, INC. | $27.10 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $24.01 | 2022 | |
| Ucb, INC. | $23.21 | 2021 | |
| Mayne Pharma Commercial LLC | $21.59 | 2019 | |
| Strata Skin Sciences, INC. | $20.91 | 2019 | |
| Genentech USA, INC. | $20.55 | 2021 | |
| Leo Pharma INC. | $19.77 | 2022 | |
| Biofrontera INC. | $18.54 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $16.56 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.58 | 2019 | |
| Aclaris Therapeutics, INC. | $13.55 | 2019 | |
| Celgene Corporation | $13.50 | 2019 | |
| Galderma Laboratories, L.P. | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.